Therefore, future research efforts will be necessary to clarify the mechanism of enzyme inhibition played by auranofin on GSTs
They also define who can enroll, what labs are checked, how side effects are handled, and when treatment should pause or stop
Reference: Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials by Sunil V Badve, Anika Bilal, Matthew M Y Lee, Naveed Sattar, Hertzel C Gerstein, Christian T Ruff, John J V McMurray, Peter Rossing, George Bakris, Kenneth W Mahaffey, Johannes F E Mann, Helen M Colhoun, Katherine R Tuttle, Richard E Pratley and Vlado Perkovic, 25 November 2024, The Lancet Diabetes & Endocrinology
CMS should closely monitor prior authorizations and denials to ensure patients can access GLP-1s
Walk away feeling educated and empowered on your GLP-1 journey, instead of lost in the confusion and misinformation